nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—UGT1A9—Mycophenolate mofetil—systemic lupus erythematosus	0.0394	0.0715	CbGbCtD
Sorafenib—UGT1A1—Mycophenolate mofetil—systemic lupus erythematosus	0.0323	0.0585	CbGbCtD
Sorafenib—ABCG2—Leflunomide—systemic lupus erythematosus	0.0287	0.0521	CbGbCtD
Sorafenib—ABCC2—Mycophenolate mofetil—systemic lupus erythematosus	0.0196	0.0356	CbGbCtD
Sorafenib—ABCG2—Mycophenolate mofetil—systemic lupus erythematosus	0.0177	0.0322	CbGbCtD
Sorafenib—CYP3A7—Dapsone—systemic lupus erythematosus	0.0151	0.0274	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Dapsone—systemic lupus erythematosus	0.0151	0.0274	CbGbCtD
Sorafenib—ABCC2—Cyclosporine—systemic lupus erythematosus	0.0149	0.027	CbGbCtD
Sorafenib—ABCG2—Hydrocortisone—systemic lupus erythematosus	0.0142	0.0258	CbGbCtD
Sorafenib—ABCG2—Cyclosporine—systemic lupus erythematosus	0.0134	0.0244	CbGbCtD
Sorafenib—ABCC4—Methotrexate—systemic lupus erythematosus	0.0132	0.024	CbGbCtD
Sorafenib—CYP1A2—Leflunomide—systemic lupus erythematosus	0.0118	0.0215	CbGbCtD
Sorafenib—CYP3A5—Dapsone—systemic lupus erythematosus	0.0113	0.0206	CbGbCtD
Sorafenib—CYP2C8—Dapsone—systemic lupus erythematosus	0.0109	0.0198	CbGbCtD
Sorafenib—CYP2C9—Leflunomide—systemic lupus erythematosus	0.0107	0.0194	CbGbCtD
Sorafenib—CYP3A7—Hydrocortisone—systemic lupus erythematosus	0.0105	0.0191	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Hydrocortisone—systemic lupus erythematosus	0.0105	0.0191	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Cyclosporine—systemic lupus erythematosus	0.00993	0.018	CbGbCtD
Sorafenib—CYP3A7—Cyclosporine—systemic lupus erythematosus	0.00993	0.018	CbGbCtD
Sorafenib—CYP3A5—Mycophenolate mofetil—systemic lupus erythematosus	0.00983	0.0178	CbGbCtD
Sorafenib—ABCC2—Dexamethasone—systemic lupus erythematosus	0.0098	0.0178	CbGbCtD
Sorafenib—CYP2C8—Mycophenolate mofetil—systemic lupus erythematosus	0.00945	0.0171	CbGbCtD
Sorafenib—CYP2C19—Dapsone—systemic lupus erythematosus	0.00915	0.0166	CbGbCtD
Sorafenib—ABCG2—Dexamethasone—systemic lupus erythematosus	0.00886	0.0161	CbGbCtD
Sorafenib—ABCB1—Methylprednisolone—systemic lupus erythematosus	0.00844	0.0153	CbGbCtD
Sorafenib—CYP3A5—Hydrocortisone—systemic lupus erythematosus	0.00789	0.0143	CbGbCtD
Sorafenib—ABCC2—Methotrexate—systemic lupus erythematosus	0.00787	0.0143	CbGbCtD
Sorafenib—CYP2C9—Dapsone—systemic lupus erythematosus	0.0076	0.0138	CbGbCtD
Sorafenib—CYP2C8—Hydrocortisone—systemic lupus erythematosus	0.00759	0.0138	CbGbCtD
Sorafenib—CYP3A5—Cyclosporine—systemic lupus erythematosus	0.00745	0.0135	CbGbCtD
Sorafenib—CYP2C8—Cyclosporine—systemic lupus erythematosus	0.00716	0.013	CbGbCtD
Sorafenib—ABCG2—Methotrexate—systemic lupus erythematosus	0.00712	0.0129	CbGbCtD
Sorafenib—CYP3A7—Dexamethasone—systemic lupus erythematosus	0.00654	0.0119	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Dexamethasone—systemic lupus erythematosus	0.00654	0.0119	CbGbCtD
Sorafenib—ABCB1—Mycophenolate mofetil—systemic lupus erythematosus	0.0064	0.0116	CbGbCtD
Sorafenib—CYP2C19—Prednisone—systemic lupus erythematosus	0.00634	0.0115	CbGbCtD
Sorafenib—CYP2B6—Dexamethasone—systemic lupus erythematosus	0.00623	0.0113	CbGbCtD
Sorafenib—CYP2C19—Cyclosporine—systemic lupus erythematosus	0.00601	0.0109	CbGbCtD
Sorafenib—ABCB1—Betamethasone—systemic lupus erythematosus	0.00549	0.00995	CbGbCtD
Sorafenib—ABCB1—Prednisolone—systemic lupus erythematosus	0.00542	0.00982	CbGbCtD
Sorafenib—ABCB1—Hydrocortisone—systemic lupus erythematosus	0.00513	0.00931	CbGbCtD
Sorafenib—ABCB1—Prednisone—systemic lupus erythematosus	0.00512	0.00928	CbGbCtD
Sorafenib—CYP3A4—Methylprednisolone—systemic lupus erythematosus	0.00506	0.00917	CbGbCtD
Sorafenib—CYP2C9—Cyclosporine—systemic lupus erythematosus	0.005	0.00906	CbGbCtD
Sorafenib—CYP3A5—Dexamethasone—systemic lupus erythematosus	0.00491	0.0089	CbGbCtD
Sorafenib—ABCB1—Cyclosporine—systemic lupus erythematosus	0.00485	0.00879	CbGbCtD
Sorafenib—CYP2C8—Dexamethasone—systemic lupus erythematosus	0.00472	0.00855	CbGbCtD
Sorafenib—CYP2D6—Cyclosporine—systemic lupus erythematosus	0.00457	0.00828	CbGbCtD
Sorafenib—CYP3A4—Dapsone—systemic lupus erythematosus	0.00442	0.00802	CbGbCtD
Sorafenib—CYP2C19—Dexamethasone—systemic lupus erythematosus	0.00396	0.00718	CbGbCtD
Sorafenib—CYP3A4—Mycophenolate mofetil—systemic lupus erythematosus	0.00383	0.00695	CbGbCtD
Sorafenib—CYP3A4—Triamcinolone—systemic lupus erythematosus	0.00383	0.00695	CbGbCtD
Sorafenib—CYP2C9—Dexamethasone—systemic lupus erythematosus	0.00329	0.00597	CbGbCtD
Sorafenib—CYP3A4—Betamethasone—systemic lupus erythematosus	0.00329	0.00596	CbGbCtD
Sorafenib—CYP3A4—Prednisolone—systemic lupus erythematosus	0.00325	0.00588	CbGbCtD
Sorafenib—ABCB1—Dexamethasone—systemic lupus erythematosus	0.00319	0.00579	CbGbCtD
Sorafenib—CYP3A4—Hydrocortisone—systemic lupus erythematosus	0.00308	0.00558	CbGbCtD
Sorafenib—CYP3A4—Prednisone—systemic lupus erythematosus	0.00306	0.00556	CbGbCtD
Sorafenib—CYP2D6—Dexamethasone—systemic lupus erythematosus	0.00301	0.00546	CbGbCtD
Sorafenib—CYP3A4—Cyclosporine—systemic lupus erythematosus	0.00291	0.00527	CbGbCtD
Sorafenib—ABCB1—Methotrexate—systemic lupus erythematosus	0.00257	0.00465	CbGbCtD
Sorafenib—CDK7—Mycophenolic acid—Mycophenolate mofetil—systemic lupus erythematosus	0.00256	0.736	CbGdCrCtD
Sorafenib—CYP3A4—Dexamethasone—systemic lupus erythematosus	0.00191	0.00347	CbGbCtD
Sorafenib—FLT4—endothelium—systemic lupus erythematosus	0.00134	0.0105	CbGeAlD
Sorafenib—FLT3—blood plasma—systemic lupus erythematosus	0.00131	0.0103	CbGeAlD
Sorafenib—MUSK—nervous system—systemic lupus erythematosus	0.00126	0.00996	CbGeAlD
Sorafenib—FLT1—endothelium—systemic lupus erythematosus	0.00104	0.0082	CbGeAlD
Sorafenib—CDKL2—nervous system—systemic lupus erythematosus	0.00103	0.00812	CbGeAlD
Sorafenib—CDKL2—central nervous system—systemic lupus erythematosus	0.000991	0.00782	CbGeAlD
Sorafenib—RALBP1—blood plasma—systemic lupus erythematosus	0.000971	0.00766	CbGeAlD
Sorafenib—CDK7—connective tissue—systemic lupus erythematosus	0.000968	0.00764	CbGeAlD
Sorafenib—MAPK15—nervous system—systemic lupus erythematosus	0.000927	0.00731	CbGeAlD
Sorafenib—FLT1—blood plasma—systemic lupus erythematosus	0.000923	0.00728	CbGeAlD
Sorafenib—CDK7—Sulfathiazole—Dapsone—systemic lupus erythematosus	0.000922	0.264	CbGdCrCtD
Sorafenib—MAPK15—central nervous system—systemic lupus erythematosus	0.000892	0.00704	CbGeAlD
Sorafenib—KDR—endothelium—systemic lupus erythematosus	0.000879	0.00693	CbGeAlD
Sorafenib—STK10—blood plasma—systemic lupus erythematosus	0.000874	0.0069	CbGeAlD
Sorafenib—CYP2C19—urine—systemic lupus erythematosus	0.000857	0.00676	CbGeAlD
Sorafenib—UGT1A1—blood plasma—systemic lupus erythematosus	0.000825	0.00651	CbGeAlD
Sorafenib—HIPK3—connective tissue—systemic lupus erythematosus	0.000818	0.00646	CbGeAlD
Sorafenib—HIPK3—nephron tubule—systemic lupus erythematosus	0.000793	0.00626	CbGeAlD
Sorafenib—KDR—blood plasma—systemic lupus erythematosus	0.00078	0.00616	CbGeAlD
Sorafenib—KIT—endothelium—systemic lupus erythematosus	0.000779	0.00614	CbGeAlD
Sorafenib—CSF1R—blood plasma—systemic lupus erythematosus	0.000762	0.00601	CbGeAlD
Sorafenib—CDK7—lymphoid tissue—systemic lupus erythematosus	0.000708	0.00558	CbGeAlD
Sorafenib—CYP1A2—urine—systemic lupus erythematosus	0.0007	0.00552	CbGeAlD
Sorafenib—HIPK3—kidney—systemic lupus erythematosus	0.000697	0.0055	CbGeAlD
Sorafenib—FLT3—connective tissue—systemic lupus erythematosus	0.000696	0.00549	CbGeAlD
Sorafenib—KIT—blood plasma—systemic lupus erythematosus	0.000692	0.00546	CbGeAlD
Sorafenib—EPHX2—nephron tubule—systemic lupus erythematosus	0.000679	0.00536	CbGeAlD
Sorafenib—CYP2C9—urine—systemic lupus erythematosus	0.000665	0.00524	CbGeAlD
Sorafenib—TAOK2—tendon—systemic lupus erythematosus	0.00066	0.00521	CbGeAlD
Sorafenib—AURKC—tendon—systemic lupus erythematosus	0.000655	0.00517	CbGeAlD
Sorafenib—ZAK—lymphoid tissue—systemic lupus erythematosus	0.000612	0.00483	CbGeAlD
Sorafenib—CDK7—lung—systemic lupus erythematosus	0.000584	0.00461	CbGeAlD
Sorafenib—EPHX2—cortex of kidney—systemic lupus erythematosus	0.000581	0.00459	CbGeAlD
Sorafenib—TAOK2—lung—systemic lupus erythematosus	0.000579	0.00457	CbGeAlD
Sorafenib—ZAK—tendon—systemic lupus erythematosus	0.000575	0.00454	CbGeAlD
Sorafenib—MKNK2—connective tissue—systemic lupus erythematosus	0.000572	0.00451	CbGeAlD
Sorafenib—HIPK3—tendon—systemic lupus erythematosus	0.000563	0.00444	CbGeAlD
Sorafenib—RET—connective tissue—systemic lupus erythematosus	0.000558	0.0044	CbGeAlD
Sorafenib—MKNK2—nephron tubule—systemic lupus erythematosus	0.000554	0.00437	CbGeAlD
Sorafenib—MAPK11—nervous system—systemic lupus erythematosus	0.000549	0.00434	CbGeAlD
Sorafenib—UGT1A9—kidney—systemic lupus erythematosus	0.000546	0.00431	CbGeAlD
Sorafenib—HIPK3—bone marrow—systemic lupus erythematosus	0.000545	0.0043	CbGeAlD
Sorafenib—CDK7—nervous system—systemic lupus erythematosus	0.000541	0.00427	CbGeAlD
Sorafenib—ABCC4—blood plasma—systemic lupus erythematosus	0.000538	0.00424	CbGeAlD
Sorafenib—AURKC—nervous system—systemic lupus erythematosus	0.000532	0.0042	CbGeAlD
Sorafenib—MAPK11—central nervous system—systemic lupus erythematosus	0.000529	0.00417	CbGeAlD
Sorafenib—FLT4—cortex of kidney—systemic lupus erythematosus	0.000524	0.00414	CbGeAlD
Sorafenib—CDK7—central nervous system—systemic lupus erythematosus	0.00052	0.00411	CbGeAlD
Sorafenib—FGFR1—cortex of kidney—systemic lupus erythematosus	0.000517	0.00408	CbGeAlD
Sorafenib—AURKC—central nervous system—systemic lupus erythematosus	0.000512	0.00404	CbGeAlD
Sorafenib—FLT3—lymphoid tissue—systemic lupus erythematosus	0.000509	0.00402	CbGeAlD
Sorafenib—CYP3A4—urine—systemic lupus erythematosus	0.000507	0.004	CbGeAlD
Sorafenib—ZAK—lung—systemic lupus erythematosus	0.000505	0.00398	CbGeAlD
Sorafenib—BRAF—tendon—systemic lupus erythematosus	0.000504	0.00398	CbGeAlD
Sorafenib—RALBP1—nephron tubule—systemic lupus erythematosus	0.000501	0.00395	CbGeAlD
Sorafenib—CYP2D6—urine—systemic lupus erythematosus	0.000499	0.00393	CbGeAlD
Sorafenib—HIPK3—lung—systemic lupus erythematosus	0.000494	0.0039	CbGeAlD
Sorafenib—EPHA6—nervous system—systemic lupus erythematosus	0.000493	0.00389	CbGeAlD
Sorafenib—FLT1—connective tissue—systemic lupus erythematosus	0.000491	0.00388	CbGeAlD
Sorafenib—MAP3K7—cortex of kidney—systemic lupus erythematosus	0.000489	0.00386	CbGeAlD
Sorafenib—RAF1—connective tissue—systemic lupus erythematosus	0.000489	0.00386	CbGeAlD
Sorafenib—BRAF—bone marrow—systemic lupus erythematosus	0.000488	0.00385	CbGeAlD
Sorafenib—MAP3K19—lung—systemic lupus erythematosus	0.000484	0.00382	CbGeAlD
Sorafenib—EPHX2—tendon—systemic lupus erythematosus	0.000482	0.0038	CbGeAlD
Sorafenib—FLT1—nephron tubule—systemic lupus erythematosus	0.000476	0.00376	CbGeAlD
Sorafenib—RET—kidney—systemic lupus erythematosus	0.000475	0.00375	CbGeAlD
Sorafenib—EPHA6—central nervous system—systemic lupus erythematosus	0.000474	0.00374	CbGeAlD
Sorafenib—MKNK2—cortex of kidney—systemic lupus erythematosus	0.000474	0.00374	CbGeAlD
Sorafenib—RAF1—nephron tubule—systemic lupus erythematosus	0.000473	0.00373	CbGeAlD
Sorafenib—MKNK1—cortex of kidney—systemic lupus erythematosus	0.000468	0.0037	CbGeAlD
Sorafenib—ZAK—nervous system—systemic lupus erythematosus	0.000467	0.00369	CbGeAlD
Sorafenib—FLT3—bone marrow—systemic lupus erythematosus	0.000463	0.00366	CbGeAlD
Sorafenib—FLT4—lymphoid tissue—systemic lupus erythematosus	0.000462	0.00365	CbGeAlD
Sorafenib—TIE1—lung—systemic lupus erythematosus	0.000461	0.00364	CbGeAlD
Sorafenib—PDGFRA—connective tissue—systemic lupus erythematosus	0.000461	0.00363	CbGeAlD
Sorafenib—ZAK—central nervous system—systemic lupus erythematosus	0.00045	0.00355	CbGeAlD
Sorafenib—MAP3K19—nervous system—systemic lupus erythematosus	0.000448	0.00353	CbGeAlD
Sorafenib—CYP2C19—blood plasma—systemic lupus erythematosus	0.000447	0.00353	CbGeAlD
Sorafenib—BRAF—lung—systemic lupus erythematosus	0.000442	0.00349	CbGeAlD
Sorafenib—RAF1—skin of body—systemic lupus erythematosus	0.000441	0.00348	CbGeAlD
Sorafenib—RALBP1—kidney—systemic lupus erythematosus	0.00044	0.00347	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—nephron tubule—systemic lupus erythematosus	0.000439	0.00346	CbGeAlD
Sorafenib—EPHB6—skin of body—systemic lupus erythematosus	0.000439	0.00346	CbGeAlD
Sorafenib—MAP3K19—central nervous system—systemic lupus erythematosus	0.000431	0.0034	CbGeAlD
Sorafenib—FGFR1—tendon—systemic lupus erythematosus	0.000429	0.00338	CbGeAlD
Sorafenib—RALBP1—cortex of kidney—systemic lupus erythematosus	0.000428	0.00338	CbGeAlD
Sorafenib—TIE1—nervous system—systemic lupus erythematosus	0.000427	0.00337	CbGeAlD
Sorafenib—EPHX2—lung—systemic lupus erythematosus	0.000423	0.00334	CbGeAlD
Sorafenib—FLT4—bone marrow—systemic lupus erythematosus	0.000421	0.00332	CbGeAlD
Sorafenib—FLT3—lung—systemic lupus erythematosus	0.00042	0.00331	CbGeAlD
Sorafenib—FLT1—kidney—systemic lupus erythematosus	0.000418	0.0033	CbGeAlD
Sorafenib—MKNK2—lymphoid tissue—systemic lupus erythematosus	0.000418	0.0033	CbGeAlD
Sorafenib—RAF1—kidney—systemic lupus erythematosus	0.000416	0.00328	CbGeAlD
Sorafenib—KDR—connective tissue—systemic lupus erythematosus	0.000415	0.00328	CbGeAlD
Sorafenib—MKNK1—lymphoid tissue—systemic lupus erythematosus	0.000413	0.00326	CbGeAlD
Sorafenib—TIE1—central nervous system—systemic lupus erythematosus	0.000411	0.00325	CbGeAlD
Sorafenib—RET—lymphoid tissue—systemic lupus erythematosus	0.000408	0.00322	CbGeAlD
Sorafenib—FLT1—cortex of kidney—systemic lupus erythematosus	0.000407	0.00322	CbGeAlD
Sorafenib—MAP3K7—tendon—systemic lupus erythematosus	0.000406	0.0032	CbGeAlD
Sorafenib—CSF1R—connective tissue—systemic lupus erythematosus	0.000405	0.0032	CbGeAlD
Sorafenib—RAF1—cortex of kidney—systemic lupus erythematosus	0.000405	0.0032	CbGeAlD
Sorafenib—EPHB6—cortex of kidney—systemic lupus erythematosus	0.000403	0.00318	CbGeAlD
Sorafenib—KDR—nephron tubule—systemic lupus erythematosus	0.000402	0.00318	CbGeAlD
Sorafenib—STK10—kidney—systemic lupus erythematosus	0.000396	0.00313	CbGeAlD
Sorafenib—MKNK2—tendon—systemic lupus erythematosus	0.000393	0.0031	CbGeAlD
Sorafenib—MAP3K7—bone marrow—systemic lupus erythematosus	0.000393	0.0031	CbGeAlD
Sorafenib—CYP2C8—blood plasma—systemic lupus erythematosus	0.00039	0.00308	CbGeAlD
Sorafenib—RET—tendon—systemic lupus erythematosus	0.000384	0.00303	CbGeAlD
Sorafenib—FLT4—lung—systemic lupus erythematosus	0.000381	0.00301	CbGeAlD
Sorafenib—MKNK2—bone marrow—systemic lupus erythematosus	0.000381	0.00301	CbGeAlD
Sorafenib—FGFR1—lung—systemic lupus erythematosus	0.000376	0.00297	CbGeAlD
Sorafenib—MKNK1—bone marrow—systemic lupus erythematosus	0.000376	0.00297	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—cortex of kidney—systemic lupus erythematosus	0.000376	0.00297	CbGeAlD
Sorafenib—UGT1A1—kidney—systemic lupus erythematosus	0.000374	0.00295	CbGeAlD
Sorafenib—KIT—connective tissue—systemic lupus erythematosus	0.000368	0.00291	CbGeAlD
Sorafenib—CSF1R—skin of body—systemic lupus erythematosus	0.000366	0.00289	CbGeAlD
Sorafenib—CYP1A2—blood plasma—systemic lupus erythematosus	0.000365	0.00288	CbGeAlD
Sorafenib—PDGFRB—connective tissue—systemic lupus erythematosus	0.00036	0.00284	CbGeAlD
Sorafenib—FLT1—lymphoid tissue—systemic lupus erythematosus	0.000359	0.00284	CbGeAlD
Sorafenib—RAF1—lymphoid tissue—systemic lupus erythematosus	0.000357	0.00282	CbGeAlD
Sorafenib—KIT—nephron tubule—systemic lupus erythematosus	0.000357	0.00281	CbGeAlD
Sorafenib—MAP3K7—lung—systemic lupus erythematosus	0.000356	0.00281	CbGeAlD
Sorafenib—RALBP1—tendon—systemic lupus erythematosus	0.000355	0.0028	CbGeAlD
Sorafenib—KDR—kidney—systemic lupus erythematosus	0.000354	0.00279	CbGeAlD
Sorafenib—CYP3A5—blood plasma—systemic lupus erythematosus	0.000352	0.00278	CbGeAlD
Sorafenib—CYP2B6—blood plasma—systemic lupus erythematosus	0.00035	0.00276	CbGeAlD
Sorafenib—CYP2C9—blood plasma—systemic lupus erythematosus	0.000347	0.00274	CbGeAlD
Sorafenib—MKNK2—lung—systemic lupus erythematosus	0.000345	0.00272	CbGeAlD
Sorafenib—KDR—cortex of kidney—systemic lupus erythematosus	0.000344	0.00272	CbGeAlD
Sorafenib—MAP2K5—cortex of kidney—systemic lupus erythematosus	0.000344	0.00272	CbGeAlD
Sorafenib—RALBP1—bone marrow—systemic lupus erythematosus	0.000344	0.00271	CbGeAlD
Sorafenib—MKNK1—lung—systemic lupus erythematosus	0.000341	0.00269	CbGeAlD
Sorafenib—STK10—lymphoid tissue—systemic lupus erythematosus	0.00034	0.00268	CbGeAlD
Sorafenib—FLT1—tendon—systemic lupus erythematosus	0.000338	0.00267	CbGeAlD
Sorafenib—PDGFRA—lymphoid tissue—systemic lupus erythematosus	0.000337	0.00266	CbGeAlD
Sorafenib—RAF1—tendon—systemic lupus erythematosus	0.000336	0.00265	CbGeAlD
Sorafenib—EPHB6—tendon—systemic lupus erythematosus	0.000334	0.00263	CbGeAlD
Sorafenib—KIT—skin of body—systemic lupus erythematosus	0.000332	0.00262	CbGeAlD
Sorafenib—RAF1—bone marrow—systemic lupus erythematosus	0.000325	0.00257	CbGeAlD
Sorafenib—PDGFRB—skin of body—systemic lupus erythematosus	0.000325	0.00256	CbGeAlD
Sorafenib—STK10—tendon—systemic lupus erythematosus	0.00032	0.00252	CbGeAlD
Sorafenib—MKNK2—nervous system—systemic lupus erythematosus	0.00032	0.00252	CbGeAlD
Sorafenib—PDGFRA—tendon—systemic lupus erythematosus	0.000317	0.0025	CbGeAlD
Sorafenib—MKNK1—nervous system—systemic lupus erythematosus	0.000316	0.00249	CbGeAlD
Sorafenib—KIT—kidney—systemic lupus erythematosus	0.000313	0.00247	CbGeAlD
Sorafenib—RET—nervous system—systemic lupus erythematosus	0.000312	0.00246	CbGeAlD
Sorafenib—RALBP1—lung—systemic lupus erythematosus	0.000312	0.00246	CbGeAlD
Sorafenib—STK10—bone marrow—systemic lupus erythematosus	0.00031	0.00244	CbGeAlD
Sorafenib—MKNK2—central nervous system—systemic lupus erythematosus	0.000308	0.00243	CbGeAlD
Sorafenib—PDGFRB—kidney—systemic lupus erythematosus	0.000306	0.00242	CbGeAlD
Sorafenib—KIT—cortex of kidney—systemic lupus erythematosus	0.000305	0.00241	CbGeAlD
Sorafenib—MKNK1—central nervous system—systemic lupus erythematosus	0.000304	0.0024	CbGeAlD
Sorafenib—KDR—lymphoid tissue—systemic lupus erythematosus	0.000304	0.0024	CbGeAlD
Sorafenib—RET—central nervous system—systemic lupus erythematosus	0.0003	0.00237	CbGeAlD
Sorafenib—PDGFRB—cortex of kidney—systemic lupus erythematosus	0.000298	0.00235	CbGeAlD
Sorafenib—CSF1R—lymphoid tissue—systemic lupus erythematosus	0.000296	0.00234	CbGeAlD
Sorafenib—FLT1—lung—systemic lupus erythematosus	0.000296	0.00234	CbGeAlD
Sorafenib—RAF1—lung—systemic lupus erythematosus	0.000295	0.00233	CbGeAlD
Sorafenib—EPHB6—lung—systemic lupus erythematosus	0.000293	0.00231	CbGeAlD
Sorafenib—RALBP1—nervous system—systemic lupus erythematosus	0.000289	0.00228	CbGeAlD
Sorafenib—KDR—tendon—systemic lupus erythematosus	0.000286	0.00225	CbGeAlD
Sorafenib—MAP2K5—tendon—systemic lupus erythematosus	0.000286	0.00225	CbGeAlD
Sorafenib—STK10—lung—systemic lupus erythematosus	0.000281	0.00221	CbGeAlD
Sorafenib—CSF1R—tendon—systemic lupus erythematosus	0.000279	0.0022	CbGeAlD
Sorafenib—RALBP1—central nervous system—systemic lupus erythematosus	0.000278	0.00219	CbGeAlD
Sorafenib—PDGFRA—lung—systemic lupus erythematosus	0.000278	0.00219	CbGeAlD
Sorafenib—ABCC4—nephron tubule—systemic lupus erythematosus	0.000277	0.00219	CbGeAlD
Sorafenib—KDR—bone marrow—systemic lupus erythematosus	0.000277	0.00218	CbGeAlD
Sorafenib—FLT1—nervous system—systemic lupus erythematosus	0.000275	0.00217	CbGeAlD
Sorafenib—RAF1—nervous system—systemic lupus erythematosus	0.000273	0.00215	CbGeAlD
Sorafenib—EPHB6—nervous system—systemic lupus erythematosus	0.000271	0.00214	CbGeAlD
Sorafenib—CSF1R—bone marrow—systemic lupus erythematosus	0.00027	0.00213	CbGeAlD
Sorafenib—KIT—lymphoid tissue—systemic lupus erythematosus	0.000269	0.00212	CbGeAlD
Sorafenib—ABCC2—nephron tubule—systemic lupus erythematosus	0.000268	0.00212	CbGeAlD
Sorafenib—CYP3A4—blood plasma—systemic lupus erythematosus	0.000264	0.00209	CbGeAlD
Sorafenib—FLT1—central nervous system—systemic lupus erythematosus	0.000264	0.00209	CbGeAlD
Sorafenib—PDGFRB—lymphoid tissue—systemic lupus erythematosus	0.000263	0.00207	CbGeAlD
Sorafenib—RAF1—central nervous system—systemic lupus erythematosus	0.000263	0.00207	CbGeAlD
Sorafenib—EPHB6—central nervous system—systemic lupus erythematosus	0.000261	0.00206	CbGeAlD
Sorafenib—CYP2D6—blood plasma—systemic lupus erythematosus	0.00026	0.00205	CbGeAlD
Sorafenib—STK10—nervous system—systemic lupus erythematosus	0.00026	0.00205	CbGeAlD
Sorafenib—PDGFRA—nervous system—systemic lupus erythematosus	0.000257	0.00203	CbGeAlD
Sorafenib—HTR2B—skin of body—systemic lupus erythematosus	0.000257	0.00203	CbGeAlD
Sorafenib—KDR—lung—systemic lupus erythematosus	0.000251	0.00198	CbGeAlD
Sorafenib—MAP2K5—lung—systemic lupus erythematosus	0.000251	0.00198	CbGeAlD
Sorafenib—STK10—central nervous system—systemic lupus erythematosus	0.00025	0.00197	CbGeAlD
Sorafenib—PDGFRA—central nervous system—systemic lupus erythematosus	0.000248	0.00195	CbGeAlD
Sorafenib—PDGFRB—tendon—systemic lupus erythematosus	0.000247	0.00195	CbGeAlD
Sorafenib—KIT—bone marrow—systemic lupus erythematosus	0.000245	0.00193	CbGeAlD
Sorafenib—CSF1R—lung—systemic lupus erythematosus	0.000245	0.00193	CbGeAlD
Sorafenib—ABCC4—kidney—systemic lupus erythematosus	0.000244	0.00192	CbGeAlD
Sorafenib—PDGFRB—bone marrow—systemic lupus erythematosus	0.000239	0.00189	CbGeAlD
Sorafenib—ABCC4—cortex of kidney—systemic lupus erythematosus	0.000237	0.00187	CbGeAlD
Sorafenib—HTR2B—cortex of kidney—systemic lupus erythematosus	0.000236	0.00186	CbGeAlD
Sorafenib—ABCC2—kidney—systemic lupus erythematosus	0.000236	0.00186	CbGeAlD
Sorafenib—MAP2K5—nervous system—systemic lupus erythematosus	0.000232	0.00183	CbGeAlD
Sorafenib—KDR—nervous system—systemic lupus erythematosus	0.000232	0.00183	CbGeAlD
Sorafenib—ABCC2—cortex of kidney—systemic lupus erythematosus	0.00023	0.00181	CbGeAlD
Sorafenib—CSF1R—nervous system—systemic lupus erythematosus	0.000226	0.00179	CbGeAlD
Sorafenib—MAP2K5—central nervous system—systemic lupus erythematosus	0.000223	0.00176	CbGeAlD
Sorafenib—KDR—central nervous system—systemic lupus erythematosus	0.000223	0.00176	CbGeAlD
Sorafenib—KIT—lung—systemic lupus erythematosus	0.000222	0.00175	CbGeAlD
Sorafenib—CSF1R—central nervous system—systemic lupus erythematosus	0.000218	0.00172	CbGeAlD
Sorafenib—PDGFRB—lung—systemic lupus erythematosus	0.000217	0.00171	CbGeAlD
Sorafenib—KIT—nervous system—systemic lupus erythematosus	0.000206	0.00162	CbGeAlD
Sorafenib—PDGFRB—nervous system—systemic lupus erythematosus	0.000201	0.00159	CbGeAlD
Sorafenib—KIT—central nervous system—systemic lupus erythematosus	0.000198	0.00156	CbGeAlD
Sorafenib—ABCC4—tendon—systemic lupus erythematosus	0.000197	0.00155	CbGeAlD
Sorafenib—ABCG2—nephron tubule—systemic lupus erythematosus	0.000196	0.00154	CbGeAlD
Sorafenib—HTR2B—tendon—systemic lupus erythematosus	0.000196	0.00154	CbGeAlD
Sorafenib—PDGFRB—central nervous system—systemic lupus erythematosus	0.000193	0.00153	CbGeAlD
Sorafenib—ABCC4—bone marrow—systemic lupus erythematosus	0.000191	0.0015	CbGeAlD
Sorafenib—ABCC2—tendon—systemic lupus erythematosus	0.000191	0.0015	CbGeAlD
Sorafenib—ABCB1—blood plasma—systemic lupus erythematosus	0.000187	0.00148	CbGeAlD
Sorafenib—CYP3A5—nephron tubule—systemic lupus erythematosus	0.000182	0.00143	CbGeAlD
Sorafenib—CYP2B6—nephron tubule—systemic lupus erythematosus	0.000181	0.00143	CbGeAlD
Sorafenib—CYP2C8—kidney—systemic lupus erythematosus	0.000177	0.0014	CbGeAlD
Sorafenib—ABCC4—lung—systemic lupus erythematosus	0.000173	0.00136	CbGeAlD
Sorafenib—HTR2B—lung—systemic lupus erythematosus	0.000172	0.00136	CbGeAlD
Sorafenib—HTR2C—nervous system—systemic lupus erythematosus	0.000169	0.00134	CbGeAlD
Sorafenib—CYP2B6—skin of body—systemic lupus erythematosus	0.000168	0.00133	CbGeAlD
Sorafenib—HTR2C—central nervous system—systemic lupus erythematosus	0.000163	0.00129	CbGeAlD
Sorafenib—ABCC4—nervous system—systemic lupus erythematosus	0.00016	0.00126	CbGeAlD
Sorafenib—CYP3A5—kidney—systemic lupus erythematosus	0.00016	0.00126	CbGeAlD
Sorafenib—HTR2B—nervous system—systemic lupus erythematosus	0.000159	0.00126	CbGeAlD
Sorafenib—CYP2B6—kidney—systemic lupus erythematosus	0.000159	0.00125	CbGeAlD
Sorafenib—CYP3A5—cortex of kidney—systemic lupus erythematosus	0.000156	0.00123	CbGeAlD
Sorafenib—ABCC4—central nervous system—systemic lupus erythematosus	0.000154	0.00122	CbGeAlD
Sorafenib—HTR2B—central nervous system—systemic lupus erythematosus	0.000153	0.00121	CbGeAlD
Sorafenib—CYP2B6—lymphoid tissue—systemic lupus erythematosus	0.000136	0.00108	CbGeAlD
Sorafenib—ABCG2—bone marrow—systemic lupus erythematosus	0.000135	0.00106	CbGeAlD
Sorafenib—ABCG2—lung—systemic lupus erythematosus	0.000122	0.000962	CbGeAlD
Sorafenib—CYP3A4—kidney—systemic lupus erythematosus	0.00012	0.000946	CbGeAlD
Sorafenib—CYP2D6—kidney—systemic lupus erythematosus	0.000118	0.000931	CbGeAlD
Sorafenib—CYP1A2—lung—systemic lupus erythematosus	0.000117	0.000926	CbGeAlD
Sorafenib—CYP3A5—lung—systemic lupus erythematosus	0.000113	0.000893	CbGeAlD
Sorafenib—CYP2B6—lung—systemic lupus erythematosus	0.000112	0.000888	CbGeAlD
Sorafenib—CYP2B6—nervous system—systemic lupus erythematosus	0.000104	0.000822	CbGeAlD
Sorafenib—CYP2B6—central nervous system—systemic lupus erythematosus	0.0001	0.000791	CbGeAlD
Sorafenib—Anaphylactic shock—Triamcinolone—systemic lupus erythematosus	9.69e-05	0.000648	CcSEcCtD
Sorafenib—Anaphylactic shock—Methylprednisolone—systemic lupus erythematosus	9.67e-05	0.000647	CcSEcCtD
Sorafenib—Syncope—Betamethasone—systemic lupus erythematosus	9.66e-05	0.000646	CcSEcCtD
Sorafenib—Syncope—Dexamethasone—systemic lupus erythematosus	9.66e-05	0.000646	CcSEcCtD
Sorafenib—Constipation—Mycophenolate mofetil—systemic lupus erythematosus	9.66e-05	0.000646	CcSEcCtD
Sorafenib—Pain—Mycophenolate mofetil—systemic lupus erythematosus	9.66e-05	0.000646	CcSEcCtD
Sorafenib—ABCB1—nephron tubule—systemic lupus erythematosus	9.65e-05	0.000762	CbGeAlD
Sorafenib—Arrhythmia—Prednisone—systemic lupus erythematosus	9.63e-05	0.000644	CcSEcCtD
Sorafenib—Infection—Triamcinolone—systemic lupus erythematosus	9.63e-05	0.000644	CcSEcCtD
Sorafenib—Infection—Methylprednisolone—systemic lupus erythematosus	9.61e-05	0.000642	CcSEcCtD
Sorafenib—Vomiting—Leflunomide—systemic lupus erythematosus	9.54e-05	0.000638	CcSEcCtD
Sorafenib—Shock—Triamcinolone—systemic lupus erythematosus	9.53e-05	0.000638	CcSEcCtD
Sorafenib—Alopecia—Prednisone—systemic lupus erythematosus	9.52e-05	0.000637	CcSEcCtD
Sorafenib—Shock—Methylprednisolone—systemic lupus erythematosus	9.51e-05	0.000636	CcSEcCtD
Sorafenib—Hepatobiliary disease—Methotrexate—systemic lupus erythematosus	9.49e-05	0.000635	CcSEcCtD
Sorafenib—Nervous system disorder—Methylprednisolone—systemic lupus erythematosus	9.48e-05	0.000634	CcSEcCtD
Sorafenib—Gastrointestinal pain—Cyclosporine—systemic lupus erythematosus	9.47e-05	0.000633	CcSEcCtD
Sorafenib—Loss of consciousness—Dexamethasone—systemic lupus erythematosus	9.47e-05	0.000633	CcSEcCtD
Sorafenib—Loss of consciousness—Betamethasone—systemic lupus erythematosus	9.47e-05	0.000633	CcSEcCtD
Sorafenib—Epistaxis—Methotrexate—systemic lupus erythematosus	9.46e-05	0.000633	CcSEcCtD
Sorafenib—Rash—Leflunomide—systemic lupus erythematosus	9.46e-05	0.000633	CcSEcCtD
Sorafenib—Dermatitis—Leflunomide—systemic lupus erythematosus	9.45e-05	0.000632	CcSEcCtD
Sorafenib—Mental disorder—Prednisone—systemic lupus erythematosus	9.44e-05	0.000631	CcSEcCtD
Sorafenib—Nausea—Azathioprine—systemic lupus erythematosus	9.44e-05	0.000631	CcSEcCtD
Sorafenib—Headache—Leflunomide—systemic lupus erythematosus	9.4e-05	0.000629	CcSEcCtD
Sorafenib—Skin disorder—Methylprednisolone—systemic lupus erythematosus	9.39e-05	0.000628	CcSEcCtD
Sorafenib—Erythema—Prednisone—systemic lupus erythematosus	9.38e-05	0.000627	CcSEcCtD
Sorafenib—Malnutrition—Prednisone—systemic lupus erythematosus	9.38e-05	0.000627	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Hydrocortisone—systemic lupus erythematosus	9.38e-05	0.000627	CcSEcCtD
Sorafenib—Hypertension—Dexamethasone—systemic lupus erythematosus	9.3e-05	0.000622	CcSEcCtD
Sorafenib—Hypertension—Betamethasone—systemic lupus erythematosus	9.3e-05	0.000622	CcSEcCtD
Sorafenib—Gastrointestinal pain—Mycophenolate mofetil—systemic lupus erythematosus	9.24e-05	0.000618	CcSEcCtD
Sorafenib—Urticaria—Cyclosporine—systemic lupus erythematosus	9.2e-05	0.000615	CcSEcCtD
Sorafenib—Myalgia—Betamethasone—systemic lupus erythematosus	9.17e-05	0.000613	CcSEcCtD
Sorafenib—Myalgia—Dexamethasone—systemic lupus erythematosus	9.17e-05	0.000613	CcSEcCtD
Sorafenib—Body temperature increased—Cyclosporine—systemic lupus erythematosus	9.15e-05	0.000612	CcSEcCtD
Sorafenib—Abdominal pain—Cyclosporine—systemic lupus erythematosus	9.15e-05	0.000612	CcSEcCtD
Sorafenib—Dyspepsia—Hydrocortisone—systemic lupus erythematosus	9.06e-05	0.000606	CcSEcCtD
Sorafenib—Haemoglobin—Methotrexate—systemic lupus erythematosus	9.05e-05	0.000605	CcSEcCtD
Sorafenib—Pain—Prednisolone—systemic lupus erythematosus	9.01e-05	0.000603	CcSEcCtD
Sorafenib—Haemorrhage—Methotrexate—systemic lupus erythematosus	9.01e-05	0.000602	CcSEcCtD
Sorafenib—Urticaria—Mycophenolate mofetil—systemic lupus erythematosus	8.97e-05	0.0006	CcSEcCtD
Sorafenib—Decreased appetite—Hydrocortisone—systemic lupus erythematosus	8.95e-05	0.000598	CcSEcCtD
Sorafenib—Abdominal pain—Mycophenolate mofetil—systemic lupus erythematosus	8.93e-05	0.000597	CcSEcCtD
Sorafenib—Body temperature increased—Mycophenolate mofetil—systemic lupus erythematosus	8.93e-05	0.000597	CcSEcCtD
Sorafenib—Nausea—Leflunomide—systemic lupus erythematosus	8.91e-05	0.000596	CcSEcCtD
Sorafenib—Urinary tract disorder—Methotrexate—systemic lupus erythematosus	8.9e-05	0.000595	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Hydrocortisone—systemic lupus erythematosus	8.88e-05	0.000594	CcSEcCtD
Sorafenib—Fatigue—Hydrocortisone—systemic lupus erythematosus	8.87e-05	0.000593	CcSEcCtD
Sorafenib—Urethral disorder—Methotrexate—systemic lupus erythematosus	8.83e-05	0.00059	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Triamcinolone—systemic lupus erythematosus	8.83e-05	0.00059	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methylprednisolone—systemic lupus erythematosus	8.81e-05	0.000589	CcSEcCtD
Sorafenib—Pain—Hydrocortisone—systemic lupus erythematosus	8.8e-05	0.000589	CcSEcCtD
Sorafenib—Anaphylactic shock—Betamethasone—systemic lupus erythematosus	8.79e-05	0.000588	CcSEcCtD
Sorafenib—Anaphylactic shock—Dexamethasone—systemic lupus erythematosus	8.79e-05	0.000588	CcSEcCtD
Sorafenib—Infection—Betamethasone—systemic lupus erythematosus	8.73e-05	0.000584	CcSEcCtD
Sorafenib—Infection—Dexamethasone—systemic lupus erythematosus	8.73e-05	0.000584	CcSEcCtD
Sorafenib—Anaemia—Prednisone—systemic lupus erythematosus	8.67e-05	0.00058	CcSEcCtD
Sorafenib—Shock—Betamethasone—systemic lupus erythematosus	8.65e-05	0.000579	CcSEcCtD
Sorafenib—Shock—Dexamethasone—systemic lupus erythematosus	8.65e-05	0.000579	CcSEcCtD
Sorafenib—Dyspnoea—Triamcinolone—systemic lupus erythematosus	8.64e-05	0.000578	CcSEcCtD
Sorafenib—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	8.62e-05	0.000577	CcSEcCtD
Sorafenib—Nervous system disorder—Betamethasone—systemic lupus erythematosus	8.62e-05	0.000577	CcSEcCtD
Sorafenib—Thrombocytopenia—Dexamethasone—systemic lupus erythematosus	8.61e-05	0.000576	CcSEcCtD
Sorafenib—Thrombocytopenia—Betamethasone—systemic lupus erythematosus	8.61e-05	0.000576	CcSEcCtD
Sorafenib—Angioedema—Prednisone—systemic lupus erythematosus	8.57e-05	0.000573	CcSEcCtD
Sorafenib—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	8.53e-05	0.000571	CcSEcCtD
Sorafenib—Dyspepsia—Triamcinolone—systemic lupus erythematosus	8.53e-05	0.00057	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—systemic lupus erythematosus	8.52e-05	0.00057	CcSEcCtD
Sorafenib—Dyspepsia—Methylprednisolone—systemic lupus erythematosus	8.51e-05	0.000569	CcSEcCtD
Sorafenib—ABCB1—kidney—systemic lupus erythematosus	8.48e-05	0.00067	CbGeAlD
Sorafenib—Gastrointestinal pain—Hydrocortisone—systemic lupus erythematosus	8.42e-05	0.000563	CcSEcCtD
Sorafenib—Syncope—Prednisone—systemic lupus erythematosus	8.41e-05	0.000563	CcSEcCtD
Sorafenib—Tinnitus—Methotrexate—systemic lupus erythematosus	8.4e-05	0.000562	CcSEcCtD
Sorafenib—Anorexia—Dexamethasone—systemic lupus erythematosus	8.38e-05	0.00056	CcSEcCtD
Sorafenib—Anorexia—Betamethasone—systemic lupus erythematosus	8.38e-05	0.00056	CcSEcCtD
Sorafenib—Urticaria—Prednisolone—systemic lupus erythematosus	8.37e-05	0.00056	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—systemic lupus erythematosus	8.36e-05	0.000559	CcSEcCtD
Sorafenib—Fatigue—Triamcinolone—systemic lupus erythematosus	8.35e-05	0.000559	CcSEcCtD
Sorafenib—Fatigue—Methylprednisolone—systemic lupus erythematosus	8.34e-05	0.000557	CcSEcCtD
Sorafenib—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	8.32e-05	0.000557	CcSEcCtD
Sorafenib—Asthenia—Cyclosporine—systemic lupus erythematosus	8.31e-05	0.000556	CcSEcCtD
Sorafenib—Pain—Triamcinolone—systemic lupus erythematosus	8.29e-05	0.000554	CcSEcCtD
Sorafenib—ABCB1—cortex of kidney—systemic lupus erythematosus	8.26e-05	0.000652	CbGeAlD
Sorafenib—Loss of consciousness—Prednisone—systemic lupus erythematosus	8.25e-05	0.000551	CcSEcCtD
Sorafenib—Pruritus—Cyclosporine—systemic lupus erythematosus	8.19e-05	0.000548	CcSEcCtD
Sorafenib—Urticaria—Hydrocortisone—systemic lupus erythematosus	8.18e-05	0.000547	CcSEcCtD
Sorafenib—Angiopathy—Methotrexate—systemic lupus erythematosus	8.17e-05	0.000547	CcSEcCtD
Sorafenib—Immune system disorder—Methotrexate—systemic lupus erythematosus	8.14e-05	0.000544	CcSEcCtD
Sorafenib—Body temperature increased—Hydrocortisone—systemic lupus erythematosus	8.14e-05	0.000544	CcSEcCtD
Sorafenib—Abdominal pain—Hydrocortisone—systemic lupus erythematosus	8.14e-05	0.000544	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—systemic lupus erythematosus	8.12e-05	0.000543	CcSEcCtD
Sorafenib—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	8.1e-05	0.000542	CcSEcCtD
Sorafenib—Hypertension—Prednisone—systemic lupus erythematosus	8.1e-05	0.000542	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Betamethasone—systemic lupus erythematosus	8.01e-05	0.000536	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Dexamethasone—systemic lupus erythematosus	8.01e-05	0.000536	CcSEcCtD
Sorafenib—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	7.99e-05	0.000534	CcSEcCtD
Sorafenib—Myalgia—Prednisone—systemic lupus erythematosus	7.99e-05	0.000534	CcSEcCtD
Sorafenib—Arthralgia—Prednisone—systemic lupus erythematosus	7.99e-05	0.000534	CcSEcCtD
Sorafenib—Alopecia—Methotrexate—systemic lupus erythematosus	7.96e-05	0.000532	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	7.93e-05	0.00053	CcSEcCtD
Sorafenib—Diarrhoea—Cyclosporine—systemic lupus erythematosus	7.92e-05	0.00053	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methylprednisolone—systemic lupus erythematosus	7.91e-05	0.000529	CcSEcCtD
Sorafenib—Mental disorder—Methotrexate—systemic lupus erythematosus	7.89e-05	0.000528	CcSEcCtD
Sorafenib—CYP3A4—nervous system—systemic lupus erythematosus	7.86e-05	0.000621	CbGeAlD
Sorafenib—Erythema—Methotrexate—systemic lupus erythematosus	7.84e-05	0.000524	CcSEcCtD
Sorafenib—Malnutrition—Methotrexate—systemic lupus erythematosus	7.84e-05	0.000524	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisolone—systemic lupus erythematosus	7.76e-05	0.000519	CcSEcCtD
Sorafenib—Dyspepsia—Dexamethasone—systemic lupus erythematosus	7.74e-05	0.000518	CcSEcCtD
Sorafenib—Dyspepsia—Betamethasone—systemic lupus erythematosus	7.74e-05	0.000518	CcSEcCtD
Sorafenib—CYP2D6—nervous system—systemic lupus erythematosus	7.74e-05	0.000611	CbGeAlD
Sorafenib—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	7.73e-05	0.000517	CcSEcCtD
Sorafenib—Urticaria—Triamcinolone—systemic lupus erythematosus	7.7e-05	0.000515	CcSEcCtD
Sorafenib—Urticaria—Methylprednisolone—systemic lupus erythematosus	7.68e-05	0.000514	CcSEcCtD
Sorafenib—Dysgeusia—Methotrexate—systemic lupus erythematosus	7.68e-05	0.000514	CcSEcCtD
Sorafenib—Body temperature increased—Triamcinolone—systemic lupus erythematosus	7.66e-05	0.000512	CcSEcCtD
Sorafenib—Dizziness—Cyclosporine—systemic lupus erythematosus	7.66e-05	0.000512	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisone—systemic lupus erythematosus	7.66e-05	0.000512	CcSEcCtD
Sorafenib—Abdominal pain—Methylprednisolone—systemic lupus erythematosus	7.64e-05	0.000511	CcSEcCtD
Sorafenib—Decreased appetite—Betamethasone—systemic lupus erythematosus	7.64e-05	0.000511	CcSEcCtD
Sorafenib—Decreased appetite—Dexamethasone—systemic lupus erythematosus	7.64e-05	0.000511	CcSEcCtD
Sorafenib—Infection—Prednisone—systemic lupus erythematosus	7.61e-05	0.000509	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	7.59e-05	0.000508	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	7.59e-05	0.000508	CcSEcCtD
Sorafenib—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	7.58e-05	0.000507	CcSEcCtD
Sorafenib—Fatigue—Dexamethasone—systemic lupus erythematosus	7.58e-05	0.000507	CcSEcCtD
Sorafenib—Fatigue—Betamethasone—systemic lupus erythematosus	7.58e-05	0.000507	CcSEcCtD
Sorafenib—CYP3A4—central nervous system—systemic lupus erythematosus	7.57e-05	0.000598	CbGeAlD
Sorafenib—Shock—Prednisone—systemic lupus erythematosus	7.53e-05	0.000504	CcSEcCtD
Sorafenib—Pain—Dexamethasone—systemic lupus erythematosus	7.52e-05	0.000503	CcSEcCtD
Sorafenib—Pain—Betamethasone—systemic lupus erythematosus	7.52e-05	0.000503	CcSEcCtD
Sorafenib—Nervous system disorder—Prednisone—systemic lupus erythematosus	7.51e-05	0.000502	CcSEcCtD
Sorafenib—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	7.47e-05	0.0005	CcSEcCtD
Sorafenib—CYP2D6—central nervous system—systemic lupus erythematosus	7.45e-05	0.000588	CbGeAlD
Sorafenib—Skin disorder—Prednisone—systemic lupus erythematosus	7.44e-05	0.000497	CcSEcCtD
Sorafenib—Asthenia—Hydrocortisone—systemic lupus erythematosus	7.38e-05	0.000494	CcSEcCtD
Sorafenib—Vomiting—Cyclosporine—systemic lupus erythematosus	7.36e-05	0.000492	CcSEcCtD
Sorafenib—Rash—Cyclosporine—systemic lupus erythematosus	7.3e-05	0.000488	CcSEcCtD
Sorafenib—Anorexia—Prednisone—systemic lupus erythematosus	7.3e-05	0.000488	CcSEcCtD
Sorafenib—Dermatitis—Cyclosporine—systemic lupus erythematosus	7.29e-05	0.000488	CcSEcCtD
Sorafenib—ABCB1—lymphoid tissue—systemic lupus erythematosus	7.29e-05	0.000575	CbGeAlD
Sorafenib—Pruritus—Hydrocortisone—systemic lupus erythematosus	7.28e-05	0.000487	CcSEcCtD
Sorafenib—Headache—Cyclosporine—systemic lupus erythematosus	7.25e-05	0.000485	CcSEcCtD
Sorafenib—Anaemia—Methotrexate—systemic lupus erythematosus	7.25e-05	0.000485	CcSEcCtD
Sorafenib—Gastrointestinal pain—Betamethasone—systemic lupus erythematosus	7.19e-05	0.000481	CcSEcCtD
Sorafenib—Gastrointestinal pain—Dexamethasone—systemic lupus erythematosus	7.19e-05	0.000481	CcSEcCtD
Sorafenib—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	7.18e-05	0.00048	CcSEcCtD
Sorafenib—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	7.14e-05	0.000477	CcSEcCtD
Sorafenib—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	7.12e-05	0.000476	CcSEcCtD
Sorafenib—Rash—Mycophenolate mofetil—systemic lupus erythematosus	7.12e-05	0.000476	CcSEcCtD
Sorafenib—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	7.12e-05	0.000476	CcSEcCtD
Sorafenib—Headache—Mycophenolate mofetil—systemic lupus erythematosus	7.08e-05	0.000473	CcSEcCtD
Sorafenib—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	7.04e-05	0.000471	CcSEcCtD
Sorafenib—Leukopenia—Methotrexate—systemic lupus erythematosus	7.02e-05	0.000469	CcSEcCtD
Sorafenib—Urticaria—Dexamethasone—systemic lupus erythematosus	6.98e-05	0.000467	CcSEcCtD
Sorafenib—Urticaria—Betamethasone—systemic lupus erythematosus	6.98e-05	0.000467	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Prednisone—systemic lupus erythematosus	6.98e-05	0.000467	CcSEcCtD
Sorafenib—Dizziness—Prednisolone—systemic lupus erythematosus	6.97e-05	0.000466	CcSEcCtD
Sorafenib—Asthenia—Triamcinolone—systemic lupus erythematosus	6.95e-05	0.000465	CcSEcCtD
Sorafenib—Body temperature increased—Betamethasone—systemic lupus erythematosus	6.95e-05	0.000465	CcSEcCtD
Sorafenib—Abdominal pain—Betamethasone—systemic lupus erythematosus	6.95e-05	0.000465	CcSEcCtD
Sorafenib—Abdominal pain—Dexamethasone—systemic lupus erythematosus	6.95e-05	0.000465	CcSEcCtD
Sorafenib—Body temperature increased—Dexamethasone—systemic lupus erythematosus	6.95e-05	0.000465	CcSEcCtD
Sorafenib—Asthenia—Methylprednisolone—systemic lupus erythematosus	6.94e-05	0.000464	CcSEcCtD
Sorafenib—Nausea—Cyclosporine—systemic lupus erythematosus	6.88e-05	0.00046	CcSEcCtD
Sorafenib—Pruritus—Triamcinolone—systemic lupus erythematosus	6.86e-05	0.000458	CcSEcCtD
Sorafenib—Cough—Methotrexate—systemic lupus erythematosus	6.84e-05	0.000458	CcSEcCtD
Sorafenib—Pruritus—Methylprednisolone—systemic lupus erythematosus	6.84e-05	0.000457	CcSEcCtD
Sorafenib—Dizziness—Hydrocortisone—systemic lupus erythematosus	6.81e-05	0.000455	CcSEcCtD
Sorafenib—Dyspepsia—Prednisone—systemic lupus erythematosus	6.74e-05	0.000451	CcSEcCtD
Sorafenib—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	6.71e-05	0.000449	CcSEcCtD
Sorafenib—Arthralgia—Methotrexate—systemic lupus erythematosus	6.68e-05	0.000446	CcSEcCtD
Sorafenib—Myalgia—Methotrexate—systemic lupus erythematosus	6.68e-05	0.000446	CcSEcCtD
Sorafenib—Decreased appetite—Prednisone—systemic lupus erythematosus	6.66e-05	0.000445	CcSEcCtD
Sorafenib—Rash—Prednisolone—systemic lupus erythematosus	6.64e-05	0.000444	CcSEcCtD
Sorafenib—Dermatitis—Prednisolone—systemic lupus erythematosus	6.64e-05	0.000444	CcSEcCtD
Sorafenib—ABCB1—bone marrow—systemic lupus erythematosus	6.64e-05	0.000524	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	6.63e-05	0.000443	CcSEcCtD
Sorafenib—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	6.62e-05	0.000442	CcSEcCtD
Sorafenib—Fatigue—Prednisone—systemic lupus erythematosus	6.6e-05	0.000441	CcSEcCtD
Sorafenib—Headache—Prednisolone—systemic lupus erythematosus	6.6e-05	0.000441	CcSEcCtD
Sorafenib—Constipation—Prednisone—systemic lupus erythematosus	6.55e-05	0.000438	CcSEcCtD
Sorafenib—Vomiting—Hydrocortisone—systemic lupus erythematosus	6.54e-05	0.000438	CcSEcCtD
Sorafenib—Rash—Hydrocortisone—systemic lupus erythematosus	6.49e-05	0.000434	CcSEcCtD
Sorafenib—Dermatitis—Hydrocortisone—systemic lupus erythematosus	6.48e-05	0.000434	CcSEcCtD
Sorafenib—Headache—Hydrocortisone—systemic lupus erythematosus	6.45e-05	0.000431	CcSEcCtD
Sorafenib—Dizziness—Triamcinolone—systemic lupus erythematosus	6.41e-05	0.000429	CcSEcCtD
Sorafenib—Anaphylactic shock—Methotrexate—systemic lupus erythematosus	6.4e-05	0.000428	CcSEcCtD
Sorafenib—Dizziness—Methylprednisolone—systemic lupus erythematosus	6.39e-05	0.000428	CcSEcCtD
Sorafenib—Infection—Methotrexate—systemic lupus erythematosus	6.36e-05	0.000425	CcSEcCtD
Sorafenib—Asthenia—Dexamethasone—systemic lupus erythematosus	6.31e-05	0.000422	CcSEcCtD
Sorafenib—Asthenia—Betamethasone—systemic lupus erythematosus	6.31e-05	0.000422	CcSEcCtD
Sorafenib—Nervous system disorder—Methotrexate—systemic lupus erythematosus	6.28e-05	0.00042	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—systemic lupus erythematosus	6.27e-05	0.000419	CcSEcCtD
Sorafenib—Gastrointestinal pain—Prednisone—systemic lupus erythematosus	6.26e-05	0.000419	CcSEcCtD
Sorafenib—Nausea—Prednisolone—systemic lupus erythematosus	6.26e-05	0.000419	CcSEcCtD
Sorafenib—Pruritus—Betamethasone—systemic lupus erythematosus	6.22e-05	0.000416	CcSEcCtD
Sorafenib—Pruritus—Dexamethasone—systemic lupus erythematosus	6.22e-05	0.000416	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—systemic lupus erythematosus	6.22e-05	0.000416	CcSEcCtD
Sorafenib—Vomiting—Triamcinolone—systemic lupus erythematosus	6.16e-05	0.000412	CcSEcCtD
Sorafenib—Vomiting—Methylprednisolone—systemic lupus erythematosus	6.15e-05	0.000411	CcSEcCtD
Sorafenib—Nausea—Hydrocortisone—systemic lupus erythematosus	6.11e-05	0.000409	CcSEcCtD
Sorafenib—Rash—Triamcinolone—systemic lupus erythematosus	6.11e-05	0.000409	CcSEcCtD
Sorafenib—Dermatitis—Triamcinolone—systemic lupus erythematosus	6.1e-05	0.000408	CcSEcCtD
Sorafenib—Anorexia—Methotrexate—systemic lupus erythematosus	6.1e-05	0.000408	CcSEcCtD
Sorafenib—Rash—Methylprednisolone—systemic lupus erythematosus	6.1e-05	0.000408	CcSEcCtD
Sorafenib—Dermatitis—Methylprednisolone—systemic lupus erythematosus	6.09e-05	0.000407	CcSEcCtD
Sorafenib—Urticaria—Prednisone—systemic lupus erythematosus	6.08e-05	0.000407	CcSEcCtD
Sorafenib—Headache—Triamcinolone—systemic lupus erythematosus	6.07e-05	0.000406	CcSEcCtD
Sorafenib—Headache—Methylprednisolone—systemic lupus erythematosus	6.06e-05	0.000405	CcSEcCtD
Sorafenib—Abdominal pain—Prednisone—systemic lupus erythematosus	6.05e-05	0.000405	CcSEcCtD
Sorafenib—Body temperature increased—Prednisone—systemic lupus erythematosus	6.05e-05	0.000405	CcSEcCtD
Sorafenib—Diarrhoea—Betamethasone—systemic lupus erythematosus	6.02e-05	0.000402	CcSEcCtD
Sorafenib—Diarrhoea—Dexamethasone—systemic lupus erythematosus	6.02e-05	0.000402	CcSEcCtD
Sorafenib—ABCB1—lung—systemic lupus erythematosus	6.01e-05	0.000474	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Methotrexate—systemic lupus erythematosus	5.83e-05	0.00039	CcSEcCtD
Sorafenib—Dizziness—Betamethasone—systemic lupus erythematosus	5.81e-05	0.000389	CcSEcCtD
Sorafenib—Dizziness—Dexamethasone—systemic lupus erythematosus	5.81e-05	0.000389	CcSEcCtD
Sorafenib—Nausea—Triamcinolone—systemic lupus erythematosus	5.76e-05	0.000385	CcSEcCtD
Sorafenib—Nausea—Methylprednisolone—systemic lupus erythematosus	5.74e-05	0.000384	CcSEcCtD
Sorafenib—Dyspnoea—Methotrexate—systemic lupus erythematosus	5.71e-05	0.000382	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisone—systemic lupus erythematosus	5.64e-05	0.000377	CcSEcCtD
Sorafenib—Dyspepsia—Methotrexate—systemic lupus erythematosus	5.63e-05	0.000377	CcSEcCtD
Sorafenib—Vomiting—Betamethasone—systemic lupus erythematosus	5.59e-05	0.000374	CcSEcCtD
Sorafenib—Vomiting—Dexamethasone—systemic lupus erythematosus	5.59e-05	0.000374	CcSEcCtD
Sorafenib—ABCB1—nervous system—systemic lupus erythematosus	5.57e-05	0.000439	CbGeAlD
Sorafenib—Decreased appetite—Methotrexate—systemic lupus erythematosus	5.56e-05	0.000372	CcSEcCtD
Sorafenib—Rash—Betamethasone—systemic lupus erythematosus	5.54e-05	0.000371	CcSEcCtD
Sorafenib—Rash—Dexamethasone—systemic lupus erythematosus	5.54e-05	0.000371	CcSEcCtD
Sorafenib—Dermatitis—Betamethasone—systemic lupus erythematosus	5.54e-05	0.00037	CcSEcCtD
Sorafenib—Dermatitis—Dexamethasone—systemic lupus erythematosus	5.54e-05	0.00037	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	5.52e-05	0.000369	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—systemic lupus erythematosus	5.52e-05	0.000369	CcSEcCtD
Sorafenib—Headache—Betamethasone—systemic lupus erythematosus	5.51e-05	0.000368	CcSEcCtD
Sorafenib—Headache—Dexamethasone—systemic lupus erythematosus	5.51e-05	0.000368	CcSEcCtD
Sorafenib—Asthenia—Prednisone—systemic lupus erythematosus	5.49e-05	0.000367	CcSEcCtD
Sorafenib—Pain—Methotrexate—systemic lupus erythematosus	5.47e-05	0.000366	CcSEcCtD
Sorafenib—Pruritus—Prednisone—systemic lupus erythematosus	5.42e-05	0.000362	CcSEcCtD
Sorafenib—ABCB1—central nervous system—systemic lupus erythematosus	5.36e-05	0.000423	CbGeAlD
Sorafenib—Diarrhoea—Prednisone—systemic lupus erythematosus	5.24e-05	0.00035	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methotrexate—systemic lupus erythematosus	5.23e-05	0.00035	CcSEcCtD
Sorafenib—Nausea—Dexamethasone—systemic lupus erythematosus	5.22e-05	0.000349	CcSEcCtD
Sorafenib—Nausea—Betamethasone—systemic lupus erythematosus	5.22e-05	0.000349	CcSEcCtD
Sorafenib—Urticaria—Methotrexate—systemic lupus erythematosus	5.08e-05	0.00034	CcSEcCtD
Sorafenib—Dizziness—Prednisone—systemic lupus erythematosus	5.06e-05	0.000339	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—systemic lupus erythematosus	5.06e-05	0.000338	CcSEcCtD
Sorafenib—Body temperature increased—Methotrexate—systemic lupus erythematosus	5.06e-05	0.000338	CcSEcCtD
Sorafenib—Vomiting—Prednisone—systemic lupus erythematosus	4.87e-05	0.000326	CcSEcCtD
Sorafenib—Rash—Prednisone—systemic lupus erythematosus	4.83e-05	0.000323	CcSEcCtD
Sorafenib—Dermatitis—Prednisone—systemic lupus erythematosus	4.82e-05	0.000323	CcSEcCtD
Sorafenib—Headache—Prednisone—systemic lupus erythematosus	4.8e-05	0.000321	CcSEcCtD
Sorafenib—Hypersensitivity—Methotrexate—systemic lupus erythematosus	4.71e-05	0.000315	CcSEcCtD
Sorafenib—Asthenia—Methotrexate—systemic lupus erythematosus	4.59e-05	0.000307	CcSEcCtD
Sorafenib—Nausea—Prednisone—systemic lupus erythematosus	4.55e-05	0.000304	CcSEcCtD
Sorafenib—Pruritus—Methotrexate—systemic lupus erythematosus	4.53e-05	0.000303	CcSEcCtD
Sorafenib—Diarrhoea—Methotrexate—systemic lupus erythematosus	4.38e-05	0.000293	CcSEcCtD
Sorafenib—Dizziness—Methotrexate—systemic lupus erythematosus	4.23e-05	0.000283	CcSEcCtD
Sorafenib—Vomiting—Methotrexate—systemic lupus erythematosus	4.07e-05	0.000272	CcSEcCtD
Sorafenib—Rash—Methotrexate—systemic lupus erythematosus	4.03e-05	0.00027	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—systemic lupus erythematosus	4.03e-05	0.00027	CcSEcCtD
Sorafenib—Headache—Methotrexate—systemic lupus erythematosus	4.01e-05	0.000268	CcSEcCtD
Sorafenib—Nausea—Methotrexate—systemic lupus erythematosus	3.8e-05	0.000254	CcSEcCtD
Sorafenib—Vismodegib—ALB—systemic lupus erythematosus	1.66e-05	1	CrCbGaD
Sorafenib—MAP2K5—Signaling Pathways—CDKN1A—systemic lupus erythematosus	3.29e-06	1.95e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CDKN1B—systemic lupus erythematosus	3.28e-06	1.94e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CDKN1A—systemic lupus erythematosus	3.28e-06	1.94e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—RXRA—systemic lupus erythematosus	3.25e-06	1.93e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	3.25e-06	1.93e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—TGFB1—systemic lupus erythematosus	3.22e-06	1.91e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—IL2—systemic lupus erythematosus	3.22e-06	1.91e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MMP9—systemic lupus erythematosus	3.21e-06	1.91e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CDKN1A—systemic lupus erythematosus	3.2e-06	1.9e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	3.2e-06	1.9e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—EP300—systemic lupus erythematosus	3.2e-06	1.9e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CD80—systemic lupus erythematosus	3.2e-06	1.9e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—EP300—systemic lupus erythematosus	3.19e-06	1.89e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—F2—systemic lupus erythematosus	3.18e-06	1.89e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TYK2—systemic lupus erythematosus	3.17e-06	1.88e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TYK2—systemic lupus erythematosus	3.17e-06	1.88e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CDKN1B—systemic lupus erythematosus	3.16e-06	1.88e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—JAK1—systemic lupus erythematosus	3.16e-06	1.87e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	3.14e-06	1.86e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—EP300—systemic lupus erythematosus	3.13e-06	1.85e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—IL6—systemic lupus erythematosus	3.12e-06	1.85e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—EP300—systemic lupus erythematosus	3.12e-06	1.85e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CD4—systemic lupus erythematosus	3.11e-06	1.84e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NOS3—systemic lupus erythematosus	3.11e-06	1.84e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NOS3—systemic lupus erythematosus	3.11e-06	1.84e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL2—systemic lupus erythematosus	3.1e-06	1.84e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PTGS2—systemic lupus erythematosus	3.08e-06	1.83e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CD80—systemic lupus erythematosus	3.05e-06	1.81e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—EP300—systemic lupus erythematosus	3.05e-06	1.81e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—ALB—systemic lupus erythematosus	3.04e-06	1.8e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—ALB—systemic lupus erythematosus	3.04e-06	1.8e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CDKN1A—systemic lupus erythematosus	3.02e-06	1.79e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TYK2—systemic lupus erythematosus	3e-06	1.78e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—systemic lupus erythematosus	3e-06	1.78e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TYK2—systemic lupus erythematosus	3e-06	1.78e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCR5—systemic lupus erythematosus	2.99e-06	1.77e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CDKN1B—systemic lupus erythematosus	2.98e-06	1.77e-05	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	2.97e-06	1.76e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—F2—systemic lupus erythematosus	2.97e-06	1.76e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCL2—systemic lupus erythematosus	2.97e-06	1.76e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—VEGFA—systemic lupus erythematosus	2.96e-06	1.76e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CDKN1B—systemic lupus erythematosus	2.96e-06	1.75e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NOS3—systemic lupus erythematosus	2.95e-06	1.75e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2RA—systemic lupus erythematosus	2.95e-06	1.75e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NOS3—systemic lupus erythematosus	2.94e-06	1.74e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—TGFB1—systemic lupus erythematosus	2.93e-06	1.74e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL2—systemic lupus erythematosus	2.93e-06	1.73e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—C3—systemic lupus erythematosus	2.92e-06	1.73e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CDKN1B—systemic lupus erythematosus	2.92e-06	1.73e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL2—systemic lupus erythematosus	2.92e-06	1.73e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	2.92e-06	1.73e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CDKN1A—systemic lupus erythematosus	2.92e-06	1.73e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—NOS3—systemic lupus erythematosus	2.9e-06	1.72e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—NOS3—systemic lupus erythematosus	2.9e-06	1.72e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL2—systemic lupus erythematosus	2.89e-06	1.72e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—VEGFA—systemic lupus erythematosus	2.89e-06	1.71e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EP300—systemic lupus erythematosus	2.88e-06	1.71e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PPARG—systemic lupus erythematosus	2.86e-06	1.7e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CD80—systemic lupus erythematosus	2.85e-06	1.69e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PPARG—systemic lupus erythematosus	2.84e-06	1.68e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCL2—systemic lupus erythematosus	2.84e-06	1.68e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—RXRA—systemic lupus erythematosus	2.82e-06	1.67e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	2.8e-06	1.66e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—TGFB1—systemic lupus erythematosus	2.78e-06	1.65e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EP300—systemic lupus erythematosus	2.78e-06	1.65e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—TGFB1—systemic lupus erythematosus	2.78e-06	1.65e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	2.78e-06	1.65e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MMP9—systemic lupus erythematosus	2.76e-06	1.64e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CDKN1A—systemic lupus erythematosus	2.75e-06	1.63e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MMP9—systemic lupus erythematosus	2.74e-06	1.62e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CDKN1A—systemic lupus erythematosus	2.73e-06	1.62e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TGFB1—systemic lupus erythematosus	2.72e-06	1.61e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TYK2—systemic lupus erythematosus	2.7e-06	1.6e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CDKN1A—systemic lupus erythematosus	2.7e-06	1.6e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NAT2—systemic lupus erythematosus	2.7e-06	1.6e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CDKN1B—systemic lupus erythematosus	2.69e-06	1.6e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CDKN1B—systemic lupus erythematosus	2.69e-06	1.6e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—systemic lupus erythematosus	2.66e-06	1.57e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTGS2—systemic lupus erythematosus	2.66e-06	1.57e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTGS2—systemic lupus erythematosus	2.66e-06	1.57e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NOS3—systemic lupus erythematosus	2.65e-06	1.57e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCL2—systemic lupus erythematosus	2.65e-06	1.57e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TGFB1—systemic lupus erythematosus	2.65e-06	1.57e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL2—systemic lupus erythematosus	2.63e-06	1.56e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL2—systemic lupus erythematosus	2.63e-06	1.56e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EP300—systemic lupus erythematosus	2.62e-06	1.55e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	2.61e-06	1.55e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EP300—systemic lupus erythematosus	2.6e-06	1.54e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ALB—systemic lupus erythematosus	2.58e-06	1.53e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TYK2—systemic lupus erythematosus	2.57e-06	1.53e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—F2—systemic lupus erythematosus	2.57e-06	1.52e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EP300—systemic lupus erythematosus	2.57e-06	1.52e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	2.56e-06	1.51e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CDKN1B—systemic lupus erythematosus	2.55e-06	1.51e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ALB—systemic lupus erythematosus	2.55e-06	1.51e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CDKN1B—systemic lupus erythematosus	2.55e-06	1.51e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NOS3—systemic lupus erythematosus	2.53e-06	1.5e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—RXRA—systemic lupus erythematosus	2.51e-06	1.49e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TGFB1—systemic lupus erythematosus	2.5e-06	1.48e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL2—systemic lupus erythematosus	2.5e-06	1.48e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	2.5e-06	1.48e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL2—systemic lupus erythematosus	2.49e-06	1.48e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MMP9—systemic lupus erythematosus	2.49e-06	1.48e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MMP9—systemic lupus erythematosus	2.49e-06	1.48e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CDKN1A—systemic lupus erythematosus	2.48e-06	1.47e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CDKN1A—systemic lupus erythematosus	2.48e-06	1.47e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—VEGFA—systemic lupus erythematosus	2.48e-06	1.47e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—NOS3—systemic lupus erythematosus	2.46e-06	1.46e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CD80—systemic lupus erythematosus	2.46e-06	1.46e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—VEGFA—systemic lupus erythematosus	2.46e-06	1.46e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—RXRA—systemic lupus erythematosus	2.45e-06	1.45e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—NOS3—systemic lupus erythematosus	2.44e-06	1.45e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—systemic lupus erythematosus	2.43e-06	1.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TYK2—systemic lupus erythematosus	2.41e-06	1.43e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—systemic lupus erythematosus	2.39e-06	1.42e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—systemic lupus erythematosus	2.39e-06	1.42e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP9—systemic lupus erythematosus	2.37e-06	1.4e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EP300—systemic lupus erythematosus	2.36e-06	1.4e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EP300—systemic lupus erythematosus	2.36e-06	1.4e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NOS3—systemic lupus erythematosus	2.36e-06	1.4e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP9—systemic lupus erythematosus	2.36e-06	1.4e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CDKN1A—systemic lupus erythematosus	2.36e-06	1.4e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CDKN1A—systemic lupus erythematosus	2.35e-06	1.39e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	2.33e-06	1.38e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—RXRA—systemic lupus erythematosus	2.31e-06	1.37e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CDKN1B—systemic lupus erythematosus	2.3e-06	1.36e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—RXRA—systemic lupus erythematosus	2.29e-06	1.36e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCL2—systemic lupus erythematosus	2.29e-06	1.36e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TGFB1—systemic lupus erythematosus	2.28e-06	1.35e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—systemic lupus erythematosus	2.27e-06	1.35e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—systemic lupus erythematosus	2.27e-06	1.34e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TGFB1—systemic lupus erythematosus	2.26e-06	1.34e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—systemic lupus erythematosus	2.25e-06	1.34e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL2—systemic lupus erythematosus	2.25e-06	1.33e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EP300—systemic lupus erythematosus	2.24e-06	1.33e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VEGFA—systemic lupus erythematosus	2.24e-06	1.33e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VEGFA—systemic lupus erythematosus	2.24e-06	1.33e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EP300—systemic lupus erythematosus	2.24e-06	1.33e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—systemic lupus erythematosus	2.23e-06	1.32e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—systemic lupus erythematosus	2.23e-06	1.32e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—systemic lupus erythematosus	2.21e-06	1.31e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—EP300—systemic lupus erythematosus	2.21e-06	1.31e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—EP300—systemic lupus erythematosus	2.21e-06	1.31e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CDKN1B—systemic lupus erythematosus	2.19e-06	1.3e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	2.18e-06	1.29e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL2—systemic lupus erythematosus	2.14e-06	1.27e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—systemic lupus erythematosus	2.13e-06	1.26e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—systemic lupus erythematosus	2.13e-06	1.26e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	2.13e-06	1.26e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—systemic lupus erythematosus	2.12e-06	1.26e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—systemic lupus erythematosus	2.12e-06	1.26e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CDKN1A—systemic lupus erythematosus	2.12e-06	1.26e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARG—systemic lupus erythematosus	2.1e-06	1.24e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—systemic lupus erythematosus	2.1e-06	1.24e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—systemic lupus erythematosus	2.09e-06	1.24e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TYK2—systemic lupus erythematosus	2.08e-06	1.23e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—systemic lupus erythematosus	2.05e-06	1.22e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—systemic lupus erythematosus	2.05e-06	1.22e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARG—systemic lupus erythematosus	2.05e-06	1.22e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—systemic lupus erythematosus	2.05e-06	1.21e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1B—systemic lupus erythematosus	2.05e-06	1.21e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—systemic lupus erythematosus	2.04e-06	1.21e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOS3—systemic lupus erythematosus	2.04e-06	1.21e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—systemic lupus erythematosus	2.03e-06	1.2e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CDKN1A—systemic lupus erythematosus	2.02e-06	1.2e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EP300—systemic lupus erythematosus	2.02e-06	1.19e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—systemic lupus erythematosus	2e-06	1.19e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—systemic lupus erythematosus	2e-06	1.18e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—systemic lupus erythematosus	1.99e-06	1.18e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—RXRA—systemic lupus erythematosus	1.96e-06	1.16e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—systemic lupus erythematosus	1.95e-06	1.16e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—systemic lupus erythematosus	1.94e-06	1.15e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EP300—systemic lupus erythematosus	1.92e-06	1.14e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—systemic lupus erythematosus	1.91e-06	1.13e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—systemic lupus erythematosus	1.89e-06	1.12e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1A—systemic lupus erythematosus	1.89e-06	1.12e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—systemic lupus erythematosus	1.89e-06	1.12e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—systemic lupus erythematosus	1.89e-06	1.12e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—EP300—systemic lupus erythematosus	1.87e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—EP300—systemic lupus erythematosus	1.86e-06	1.1e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—systemic lupus erythematosus	1.85e-06	1.09e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—systemic lupus erythematosus	1.82e-06	1.08e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—systemic lupus erythematosus	1.82e-06	1.08e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	1.82e-06	1.08e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—systemic lupus erythematosus	1.81e-06	1.07e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EP300—systemic lupus erythematosus	1.8e-06	1.06e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—systemic lupus erythematosus	1.78e-06	1.05e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1B—systemic lupus erythematosus	1.77e-06	1.05e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—systemic lupus erythematosus	1.77e-06	1.05e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—systemic lupus erythematosus	1.75e-06	1.04e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—systemic lupus erythematosus	1.73e-06	1.02e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—systemic lupus erythematosus	1.72e-06	1.02e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—systemic lupus erythematosus	1.72e-06	1.02e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—systemic lupus erythematosus	1.7e-06	1.01e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—systemic lupus erythematosus	1.7e-06	1.01e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—systemic lupus erythematosus	1.68e-06	9.96e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—systemic lupus erythematosus	1.67e-06	9.9e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—systemic lupus erythematosus	1.65e-06	9.79e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—systemic lupus erythematosus	1.64e-06	9.69e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1A—systemic lupus erythematosus	1.63e-06	9.66e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—systemic lupus erythematosus	1.61e-06	9.57e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—systemic lupus erythematosus	1.6e-06	9.47e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—systemic lupus erythematosus	1.59e-06	9.4e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—systemic lupus erythematosus	1.56e-06	9.26e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EP300—systemic lupus erythematosus	1.55e-06	9.19e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—systemic lupus erythematosus	1.55e-06	9.18e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—systemic lupus erythematosus	1.55e-06	9.18e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—systemic lupus erythematosus	1.55e-06	9.18e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—systemic lupus erythematosus	1.53e-06	9.06e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—RXRA—systemic lupus erythematosus	1.51e-06	8.96e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—systemic lupus erythematosus	1.47e-06	8.71e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—systemic lupus erythematosus	1.47e-06	8.7e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—systemic lupus erythematosus	1.47e-06	8.69e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—systemic lupus erythematosus	1.46e-06	8.65e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—systemic lupus erythematosus	1.45e-06	8.57e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—systemic lupus erythematosus	1.43e-06	8.46e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—systemic lupus erythematosus	1.4e-06	8.29e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—systemic lupus erythematosus	1.39e-06	8.25e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—EP300—systemic lupus erythematosus	1.37e-06	8.14e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—systemic lupus erythematosus	1.36e-06	8.09e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—systemic lupus erythematosus	1.35e-06	7.99e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—EP300—systemic lupus erythematosus	1.34e-06	7.96e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—systemic lupus erythematosus	1.33e-06	7.89e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—systemic lupus erythematosus	1.32e-06	7.82e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—systemic lupus erythematosus	1.31e-06	7.78e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—systemic lupus erythematosus	1.3e-06	7.71e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—systemic lupus erythematosus	1.26e-06	7.46e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—systemic lupus erythematosus	1.26e-06	7.44e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—systemic lupus erythematosus	1.25e-06	7.4e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—systemic lupus erythematosus	1.24e-06	7.37e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—systemic lupus erythematosus	1.24e-06	7.33e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—systemic lupus erythematosus	1.22e-06	7.22e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—systemic lupus erythematosus	1.18e-06	6.97e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—EP300—systemic lupus erythematosus	1.16e-06	6.89e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—systemic lupus erythematosus	1.15e-06	6.8e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—systemic lupus erythematosus	1.14e-06	6.74e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—systemic lupus erythematosus	1.11e-06	6.59e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—systemic lupus erythematosus	1.06e-06	6.3e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—EP300—systemic lupus erythematosus	1.04e-06	6.15e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—systemic lupus erythematosus	1.02e-06	6.02e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—EP300—systemic lupus erythematosus	1.01e-06	6e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—systemic lupus erythematosus	9.72e-07	5.76e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—EP300—systemic lupus erythematosus	9.55e-07	5.66e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—systemic lupus erythematosus	9.54e-07	5.65e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—EP300—systemic lupus erythematosus	9.46e-07	5.61e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—systemic lupus erythematosus	8.58e-07	5.08e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—systemic lupus erythematosus	8.21e-07	4.86e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—EP300—systemic lupus erythematosus	8.09e-07	4.79e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—systemic lupus erythematosus	7.51e-07	4.45e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—EP300—systemic lupus erythematosus	6.24e-07	3.7e-06	CbGpPWpGaD
